An interventional study of Curcumin Topical Spray and Chlorhexidine Topical Spray in Wound Healing, Alveolitis of Jaw and Tooth Extraction, sponsored by Istanbul University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Istanbul University · Not applicable, Interventional, and Treatment
This randomized, single-blind, controlled clinical trial aims to evaluate the effects of a topical curcumin spray on post-extraction wound healing and postoperative symptoms in adults undergoing first molar extraction. Participants will be randomly assigned to one of three groups: curcumin topical spray, 0.12% chlorhexidine topical spray, or standard postoperative care without a topical spray. The interventions will be applied twice daily for 7 days. Postoperative pain will be assessed using a visual analog scale, while wound healing will be evaluated using the Landry, Turnbull, and Howley Healing Index. Wound dimensions will also be recorded during follow-up. In addition, salivary levels of inflammatory biomarkers, including interleukin-1β (IL-1β), tumor necrosis factor-alpha (TNF-α), and prostaglandin E2 (PGE2), will be analyzed to assess the local inflammatory response during the postoperative healing period.The study aims to compare the clinical effects of topical curcumin with chlorhexidine and standard postoperative care during the early healing period after tooth extraction.
This study is designed as a randomized, single-blind, three-arm controlled clinical trial to evaluate the effect of a curcumin-containing topical spray on early wound healing and postoperative symptoms following first molar extraction in adults aged 18-40 years.
Eligible participants requiring first molar extraction will undergo minimally traumatic tooth extraction without primary suturing. Following extraction, participants will be randomly allocated to one of three study groups. Participants in the curcumin group will use a Curcuma longa-containing topical spray, administered as two sprays to the extraction site twice daily for 7 days. Participants in the chlorhexidine group will use a 0.12% chlorhexidine topical spray according to the same administration schedule. Participants in the control group will receive standard postoperative care without the use of an additional topical spray.
All participants will receive standardized postoperative instructions. Clinical follow-up will be performed during the early postoperative healing period. Postoperative pain will be assessed using a 0-10 visual analog scale (VAS) on postoperative days 1, 3, 5, and 7. Soft-tissue wound healing will be evaluated using the Landry, Turnbull, and Howley Healing Index on postoperative days 7 and 14. Wound dimensions will be measured in the buccolingual and mesiodistal directions during follow-up.
In addition to clinical assessments, salivary inflammatory biomarkers, including interleukin-1 beta (IL-1β), tumor necrosis factor-alpha (TNF-α), and prostaglandin E2 (PGE2), will be analyzed to evaluate the local inflammatory response associated with postoperative healing.
The study will compare clinical healing, postoperative pain, wound dimensions, mouth opening, and inflammatory biomarker levels among the curcumin, chlorhexidine, and control groups. The aim is to determine whether topical curcumin influences early post-extraction wound healing and postoperative inflammatory symptoms compared with chlorhexidine and standard postoperative care.
41 studies on the registry are indexed under Dry Socket; 10 are open to participants now.
This study's planned enrollment of 54 is close to the median of 60 across 36 interventional studies indexed under Dry Socket.
Browse Dry Socket studies →Istanbul University is the lead sponsor of 507 studies on the registry; 80 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will receive a Curcuma longa-containing topical spray applied to the extraction site as two sprays twice daily for 7 days, in addition to standard postoperative care.
Dietary Supplement: Curcumin Topical Spray
Participants will receive a 0.12% chlorhexidine topical spray applied to the extraction site as two sprays twice daily for 7 days, in addition to standard postoperative care.
Drug: Chlorhexidine Topical Spray
Participants will receive standard postoperative care following tooth extraction without the use of an additional topical spray.
A commercially available Curcuma longa-containing topical spray (Minerelax®) will be applied directly to the extraction site as two sprays twice daily for 7 days following tooth extraction, in addition to standardized postoperative care.
0.12% chlorhexidine topical spray administered to the extraction site as two sprays twice daily for 7 days.
Also known as: Chlorhexidine 0.12% Topical Spray
Extraction Socket Healing Assessed Using the Landry, Turnbull and Howley Healing Index
Extraction socket healing will be assessed using the Landry, Turnbull and Howley Healing Index, ranging from 1 (very poor healing) to 5 (excellent healing). Higher scores indicate better wound healing. Scores will be compared among the curcumin spray, chlorhexidine spray, and standard postoperative care groups.
Time frame: postoperative 7. and 14. days
Postoperative Pain Intensity
Pain intensity at the extraction site will be assessed using a visual analog scale ranging from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicate greater pain intensity. Assessments will be performed by telephone on days 1, 3, and 5 and at the clinical visit on day 7. Scores will be compared among the three study groups.
Time frame: Postoperative days 1, 3, 5, and 7.
Change in Extraction Socket Wound Size
Wound size will be assessed by directly measuring the distance between predefined anatomical landmarks at the extraction site. Measurements on postoperative days 7 and 14 will be compared with the initial measurement obtained on day 0 and among the three study groups. A reduction in the measured distance indicates wound closure.
Time frame: Day 0 following extraction and postoperative days 7 and 14.
Change in Salivary Interleukin-1 Beta Concentration
Salivary interleukin-1 beta (IL-1 beta) concentrations will be measured using a commercial enzyme-linked immunosorbent assay (ELISA). Concentrations on postoperative days 2 and 7 and changes from the pre-extraction baseline will be compared among the three study groups to assess the local inflammatory response.
Time frame: Before extraction (day 0) and postoperative days 2 and 7.
Change in Salivary Tumor Necrosis Factor Alpha Concentration
Salivary tumor necrosis factor alpha (TNF-alpha) concentrations will be measured using a commercial enzyme-linked immunosorbent assay (ELISA). Concentrations on postoperative days 2 and 7 and changes from the pre-extraction baseline will be compared among the three study groups to assess the local inflammatory response.
Time frame: Before extraction (day 0) and postoperative days 2 and 7.
Change in Salivary Prostaglandin E2 Concentration
Salivary prostaglandin E2 (PGE2) concentrations will be measured using a commercial enzyme-linked immunosorbent assay (ELISA). Concentrations on postoperative days 2 and 7 and changes from the pre-extraction baseline will be compared among the three study groups to assess the local inflammatory response.
Time frame: Before extraction (day 0) and postoperative days 2 and 7.
Plan to share: No — Individual participant data will not be shared because a formal data-sharing plan and infrastructure have not been established for this study.
Start is estimated for Sep 2026; primary completion for Nov 2026, 2 months later.
Of 17 interventional studies with no phase under Dry Socket, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 30. This study's planned 2 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.